Anthropic partners with six companies to push Claude into drug discovery
Photo: Crypto Briefing
From antibody design to regulatory paperwork, Anthropic's AI is now working inside biotech labs, though most of the work remains preclinical Anthropic wants Claude to do more than write emails and debug code. It wants the AI to help make medicine. On October 27, 2026, the company detailed progress across collaborations with six organizations using Claude and its Claude Science workbench for drug development. It also disclosed its own in-house drug programs. Most of that work is still preclinical, which means nothing has reached a patient yet. The partner roster mixes big pharma, venture capital and startups.
Source: Crypto Briefing
